Gut Helicobacter presentation by multiple dendritic cell subsets enables context-specific regulatory T cell generation

  1. Emilie V Russler-Germain  Is a corresponding author
  2. Jaeu Yi
  3. Shannon Young
  4. Katherine Nutsch
  5. Harikesh S Wong
  6. Teresa L Ai
  7. Jiani N Chai
  8. Vivek Durai
  9. Daniel H Kaplan
  10. Ronald N Germain
  11. Kenneth M Murphy
  12. Chyi-Song Hsieh  Is a corresponding author
  1. Washington University in St Louis, United States
  2. National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
  3. University of Pittsburgh, United States

Abstract

Generation of tolerogenic peripheral regulatory T (pTreg) cells is commonly thought to involve CD103+ gut dendritic cells (DCs), yet their role in commensal-reactive pTreg development is unclear. Using two Helicobacter-specific T cell receptor (TCR) transgenic mouse lines, we found that both CD103+ and CD103 migratory, but not resident, DCs from the colon-draining mesenteric lymph node presented Helicobacter antigens to T cells ex vivo. Loss of most CD103+ migratory DCs in vivo using murine genetic models did not affect the frequency of Helicobacter-specific pTreg cell generation or induce compensatory tolerogenic changes in the remaining CD103 DCs. By contrast, activation in a Th1-promoting niche in vivo blocked Helicobacter-specific pTreg generation. Thus, these data suggest a model where DC-mediated effector T cell differentiation is 'dominant', necessitating that all DC subsets presenting antigen are permissive for pTreg cell induction to maintain gut tolerance.

Data availability

16S rRNA sequencing data has been deposited in ENA (PRJEB42640).

The following data sets were generated

Article and author information

Author details

  1. Emilie V Russler-Germain

    Internal Medicine, Washington University in St Louis, Saint Louis, United States
    For correspondence
    russler@wustl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2036-6697
  2. Jaeu Yi

    Internal Medicine, Washington University in St Louis, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Shannon Young

    Internal Medicine, Washington University in St Louis, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Katherine Nutsch

    Internal Medicine, Washington University in St Louis, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Harikesh S Wong

    Lymphocyte Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Teresa L Ai

    Internal Medicine, Washington University in St Louis, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Jiani N Chai

    Internal Medicine, Washington University in St Louis, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2560-8218
  8. Vivek Durai

    Pathology, Washington University in St Louis, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Daniel H Kaplan

    Dermatology and Immunology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Ronald N Germain

    Lymphocyte Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1495-9143
  11. Kenneth M Murphy

    Department of Pathology and Immunology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Chyi-Song Hsieh

    Internal Medicine, Washington University in St Louis, Saint Louis, United States
    For correspondence
    chsieh@wustl.edu
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Institutes of Health (R01 AI079187)

  • Chyi-Song Hsieh

National Institutes of Health (R01 AI136515)

  • Chyi-Song Hsieh

Burroughs Wellcome Fund

  • Chyi-Song Hsieh

National Institutes of Health (F30 DK111071)

  • Emilie V Russler-Germain

National Institutes of Health (T32 GM007200)

  • Emilie V Russler-Germain

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments were performed in strict accordance with the guidelines of the Institutional Animal Care and Use Committee at Washington University (Protocol Number: 20170036).

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,893
    views
  • 308
    downloads
  • 23
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Emilie V Russler-Germain
  2. Jaeu Yi
  3. Shannon Young
  4. Katherine Nutsch
  5. Harikesh S Wong
  6. Teresa L Ai
  7. Jiani N Chai
  8. Vivek Durai
  9. Daniel H Kaplan
  10. Ronald N Germain
  11. Kenneth M Murphy
  12. Chyi-Song Hsieh
(2021)
Gut Helicobacter presentation by multiple dendritic cell subsets enables context-specific regulatory T cell generation
eLife 10:e54792.
https://doi.org/10.7554/eLife.54792

Share this article

https://doi.org/10.7554/eLife.54792

Further reading

    1. Immunology and Inflammation
    Shih-Wen Huang, Yein-Gei Lai ... Nan-Shih Liao
    Research Article

    Natural killer (NK) cells can control metastasis through cytotoxicity and IFN-γ production independently of T cells in experimental metastasis mouse models. The inverse correlation between NK activity and metastasis incidence supports a critical role for NK cells in human metastatic surveillance. However, autologous NK cell therapy has shown limited benefit in treating patients with metastatic solid tumors. Using a spontaneous metastasis mouse model of MHC-I+ breast cancer, we found that transfer of IL-15/IL-12-conditioned syngeneic NK cells after primary tumor resection promoted long-term survival of mice with low metastatic burden and induced a tumor-specific protective T cell response that is essential for the therapeutic effect. Furthermore, NK cell transfer augments activation of conventional dendritic cells (cDCs), Foxp3-CD4+ T cells and stem cell-like CD8+ T cells in metastatic lungs, to which IFN-γ of the transferred NK cells contributes significantly. These results imply direct interactions between transferred NK cells and endogenous cDCs to enhance T cell activation. We conducted an investigator-initiated clinical trial of autologous NK cell therapy in six patients with advanced cancer and observed that the NK cell therapy was safe and showed signs of effectiveness. These findings indicate that autologous NK cell therapy is effective in treating established low burden metastases of MHC-I+ tumor cells by activating the cDC-T cell axis at metastatic sites.

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Patsy R Tomlinson, Rachel G Knox ... Robert K Semple
    Research Article

    PIK3R1 encodes three regulatory subunits of class IA phosphoinositide 3-kinase (PI3K), each associating with any of three catalytic subunits, namely p110α, p110β, or p110δ. Constitutional PIK3R1 mutations cause diseases with a genotype-phenotype relationship not yet fully explained: heterozygous loss-of-function mutations cause SHORT syndrome, featuring insulin resistance and short stature attributed to reduced p110α function, while heterozygous activating mutations cause immunodeficiency, attributed to p110δ activation and known as APDS2. Surprisingly, APDS2 patients do not show features of p110α hyperactivation, but do commonly have SHORT syndrome-like features, suggesting p110α hypofunction. We sought to investigate this. In dermal fibroblasts from an APDS2 patient, we found no increased PI3K signalling, with p110δ expression markedly reduced. In preadipocytes, the APDS2 variant was potently dominant negative, associating with Irs1 and Irs2 but failing to heterodimerise with p110α. This attenuation of p110α signalling by a p110δ-activating PIK3R1 variant potentially explains co-incidence of gain-of-function and loss-of-function PIK3R1 phenotypes.